Novo Nordisk warns on sales and operating profit:
This article was originally published in Clinica
Danish company Novo Nordisk has warned that its first-quarter sales have been lower than expected and that full-year sales are not likely to reach previously forecast levels. The company has reduced expectations for full-year operating profit growth from 15% to 5-10%. The Bagsvaerd-based company attributes the poor performance in part to the fact that sales growth of insulin products in Europe have been hit by a slower than expected conversion to analogs and new devices.
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.